Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune FluMist

Executive Summary

MedImmune submits answers to FDA's "complete response" letter for nasal flu vaccine FluMist Aug. 26. Company hopes for approval in time for the winter flu season (1"The Pink Sheet" July 15, p. 19)...

You may also be interested in...

Medimmune FluMist Indication Could Exclude Patients With Asthma

MedImmune could carve out a subpopulation of FluMist patients who suffer from wheezing and asthma from the proposed indication for the intranasal vaccine, the company said following receipt of a complete response letter from FDA

FDA OK’s Insomnia Treatment Through Software Pre-Cert Program

Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.

Neuraxpharm Allies With Panaxia On Cannabis Portfolio

CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts